Researchclopedia
Research
Researchers
Institutions
Topics
Submit
About
Search...
⌘
K
Command Palette
Search for a command to run...
Back to research
Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial
2022
52 citations
Journal Article
gold Open Access
Field-Weighted Citation Impact:
5.13
Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial | Researchclopedia
·
University Hospital Heidelberg
Mauricio Burotto
Hakim Mahammedi
·
Centre Jean Perrin
Gwénaëlle Gravis
·
Institut Paoli-Calmettes
Diogo Assed Bastos
·
Hospital Sírio-Libanês
Steven McCune
·
WellStar Health System
Juan Carlos Vázquez Limón
·
Instituto Jalisciense de Cancerología
Edmond M. Kwan
·
Monash Health
Daniel Castellano
·
Hospital Universitario 12 De Octubre
Aude Fléchon
·
Centre Léon Bérard
Fred Saad
·
Centre Hospitalier de l’Université de Montréal
Marc‐Oliver Grimm
·
Jena University Hospital
David R. Shaffer
·
New York Oncology Hematology
Andrew J. Armstrong
·
Duke University
Prabhu Bhagavatheeswaran
·
Bristol-Myers Squibb (United States)
Neha P. Amin
·
Bristol-Myers Squibb (United States)
Keziban Ünsal-Kaçmaz
·
Bristol-Myers Squibb (United States)
Xuya Wang
·
Predictive Science (United States)
Jun Li
·
Predictive Science (United States)
Andrea Loehr
·
Clovis Oncology (United States)
Russell K. Pachynski
·
Washington University in St. Louis